Other studies have identified direct cytotoxicity of CD47-targeting therapies on CD47+ cancer cells (83–85), but therapies targeting the SIRPα binding epitope do not cause direct cytotoxicity on tumor cells (41, 63). This evidence concerns the gene SIRPA and cancer.